<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840489</url>
  </required_header>
  <id_info>
    <org_study_id>RIBACIR-1</org_study_id>
    <nct_id>NCT00840489</nct_id>
  </id_info>
  <brief_title>Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis</brief_title>
  <acronym>RIBACIR</acronym>
  <official_title>Phase II Trial of Long-term Monotherapy With Ribavirin Against Colchicine on Progression of Chronic Hepatitis C With Advanced Fibrosis in Patients With Non-response to Standard Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rate of sustained virological response to a course of standard antiviral therapy
      (peg-interferon plus ribavirin) of patients with chronic hepatitis C infected by genotype 1
      with advanced fibrosis (&gt;F2) is rather low. Monotherapy with ribavirin reduces ALT levels and
      necroinflammatory liver activity in up to a half of non-responders to standard antiviral
      therapy, but without changes in liver fibrosis or viremia. Such a beneficial effect seems to
      be mainly due to the immunomodulatory effect of ribavirin. Portal pressure, as measured by
      HVPG, lowers in patients with chronic hepatitis C and advanced fibrosis with end-of-treatment
      response to peg-interferon plus ribavirin. Portal pressure reduction in this setting relates
      to a reduction of the necroinflammatory liver activity, but not with fibrosis amelioration.
      We hypothesize that monotherapy with ribavirin reduces portal pressure in hepatitis C
      patients with advanced fibrosis by means of its immunomodulatory and anti-inflammatory
      effects, and could constitute an alternative to non-responders to standard antiviral
      treatment. Portal pressure measurement has become a validated surrogate outcome measure in
      chronic liver disease, since decreasing portal pressure has shown consistent improvement in
      survival and clinical outcomes, such as complications of portal hypertension. The primary aim
      of this study is to investigate whether ribavirin monotherapy slows the progression of
      advanced chronic liver disease by hepatitis C as assessed by a reduction in HVPG.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Preliminary analysis
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic disease progression defined by a difference of &gt;2 mmHg in the hepatic venous gradient between the basal values and the end of treatment values in both groups</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in the necroinflammatory activity and in the progression of fibrosis. Normalization of ALT levels.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribavirin 1000-1200 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.5 mg bd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin 1000-1200 mg qd for 24 weeks</description>
    <arm_group_label>Ribavirin</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.5 mg bd for 24 weeks</description>
    <arm_group_label>Colchicine</arm_group_label>
    <other_name>Colchimax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA in serum

          -  AST/ALT greater than the upper limit of normal range

          -  HVPG &gt;5 mm Hg

          -  Non-response or contraindication to a standard course of antiviral therapy

        Exclusion Criteria:

          -  Active alcoholism

          -  HIV infection

          -  Serum creatinine &gt;1.2 mg/dl, hemoglobin &lt;11 g/dl, hemolysis, symptomatic ischemic
             heart disease or cerebrovascular disease

          -  Decompensated chronic liver disease

          -  Pregnancy

          -  Hypersensitivity to the drugs of the study

          -  Severe concomitant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustín Albillos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Calleja, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Bañares, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Agustin Albillos</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

